Depomed prevails in Nucynta ER patent litigation
US specialty drugmaker Depomed (Nasdaq: DEPO) has received a favorable Markman claim construction ruling by Judge Claire Cecchi of the US District Court for the District of New Jersey, which has been issued in the ongoing patent infringement case against the three filers of Abbreviated New Drug Applications (ANDA) with Depomed prevailing on all disputed claims.
These filers are seeking to market generic versions of Nucynta (tapentadol) and Nucynta ER (tapentadol) extended released tablets.
In a Markman ruling, also known as a Claim Construction Ruling, the court determines the meaning of disputed patent terms at issue in patent litigation. Judge Cecchi construed all disputed patent terms as proposed by plaintiffs Depomed and its licensor, Germany’s Grünenthal GmbH.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze